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Transforming growth factor a (TGFa) is a 5.6 kd single-chain polypeptide that acts through
binding to the epidermal growth factor receptor (EGFR). TGFa is produced in awide range of
normal as well as embryonic and neoplastic cells and tissues. TGFa and EGFR, but not EGF,
are expressed in normal gastric mucosa. We have identified the following biological roles for
TGFa in the stomach, usingavarietyofprimate and rodentmodels: inhibition ofacid secretion;
stimulation of mucous cell growth; protection against ethanol- and aspirin-induced injury. This
last effect is associated with a time- and dose-dependent increase in levels of insoluble gastric
mucin.
Based on these known biological actions of TGFa, we have examined TGFa production in
Menetrier's disease, a disorder characterized by foveolar hyperplasia, hypochlorhydria, and
increased gastric mucin content. In four patients with Menetrier's disease, there was enhanced
TGFa immunostaining throughout the gastric mucosa. Furthermore, metallothionein (MT)-
TGFa transgenic mice which overproduce TGFa in the stomach exhibit histopathological and
biochemical features characteristic ofand consistent with the diagnosis ofMenetrier's disease.
Thus locally producedTGFa maymediate a numberofbiological processes in the stomach, and
its altered production may participate in the pathogenesis ofselected pathological states.
INTRODUCTION
The purpose ofthis article is to reviewwork, in large part from this laboratory, on
theroleofTGFainselectedaspectsofgastricphysiology,anditsapparentdysregulationin
Menetrier's disease. Before doing so,wewill summarize recent advances in the study
of TGFa and attempt to place this peptide into the context of EGF and other
EGF-like molecules, with special emphasis on the gastrointestinal tract. This review
is not intended tobe comprehensive and in partwill be highly speculative.
BACKGROUND
DiscoveryofTransforning Growth Factors
Transforming growth factors (TGFs) were first identified in 1978 in medium
conditioned by fibroblasts transformed by the Rous sarcoma virus [1]. Addition of
this partially purified material to normal fibroblasts caused the reversible appear-
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ance ofa malignant (transformed) phenotype. Consequently, the protein was named
transforming growth factor. Later it was shown that this transforming activity was
composed of two distinct proteins, now designated TGFa and TGF,B [2]. It was
postulated that TGFot functioned in an autocrine manner and that overexpression of
this protein might contribute to malignant transformation [3]. Since TGFa was also
observed in embryonic cells and tissues [4,5], it was suggested that TGFa was an
embryonic growth factor inappropriately expressed in neoplasia.
Structure ofthe TGFct Gene andProtein
The human TGFa gene spans 70-100 kb on chromosome 2 and contains six exons
[6,7]. The 4.5-4.8 kb TGFa mRNA transcript encodes a 160 amino acid peptide,
which is schematically depicted in Fig. 1. A signal peptide in the amino terminus is
presumably cleaved prior to exit from the cell. N- and 0-linkedglycosylation sites are
indicated by the asterisks. The 50 amino acid polypeptide is produced by proteolytic
cleavage of the ALA VAL VAL residues that flank either end of the mature
molecule. Six cysteine residues in the mature peptide form three disulfide bridges.
There is a hydrophobic transmembrane region followed by an intracellular cytoplas-
mictailwith sevencysteine residues, someofwhich arecovalentlylinked topalmitate
[8].
The reported sizes ofthe TGFa protein range from 5 to 20 kd. This variation may
reflect differential glycosylation and proteolytic cleavage, aswell as dimerization and
the presence ofbinding proteins. Possible distinct biological roles ofTGFa forms of
higher molecular weight have not been explored. In a number of TGFa expressing
cell lines, the protein is detected in cell extracts but not in the conditioned medium
[9]. The biological significance of this observation has been explored in parallel by
two independent groups [10,11]. The arrows in Fig. 1 indicate sites of mutation
engineered by these investigators that result in membrane fixation of TGFa. These
mutated forms of TGFa are able to activate epidermal growth factor (EGF)
receptors on neighboring cells. This observation has important implications for the
actions ofTGFa; e.g., this cell-cell stimulation ("juxtacrine" stimulation) might play
a role in developmental processes that depend on discrete cell-cell interactions, or it
might target proTGFa expressing cells to tissue sites rich in EGFR [12,13]. There is
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increasing evidence that local production/processing ofTGFa may confer biological
consequences distinctfromsystemicdelivery/exogenous administrationofthegrowth
factor [14].
TheEGF/TGFatReceptor
There is 35 percent structural identity between TGFa and EGF; however, all six
cysteine residues are conserved, and formation of three disulfide bridges imparts
sufficient structural identity for both peptides to bind to the epidermal growth factor
receptor (EGFR) [15]. The EGFR is a 170 kd protein that consists of a cell surface
ligand receptor domain, a single hydrophobic transmembrane segment, and a highly
conserved cytoplasmic tyrosine kinase domain. Binding of EGF or TGFa to the
receptor initiates a complex program of activation of intrinsic kinase activity,
increases in cytosolic calcium, and ultimately DNA synthesis and cellular growth. In
addition, clustering and dimerization of receptors occurs with binding of ligand to
cell surface receptor, followed by internalization and degradation of the ligand/
receptor complexes within lysosomes. A 65 amino acid cytoplasmic stretch of the
EGFR has been identified, one that mediates the increase in cytoplasmic calcium
and ligand/receptor internalization (the CAIN domain) [16]. Activation of the
EGFR tyrosine kinase appears to be necessary for subsequent biological activity. An
active area of research is identification of substrates for this tyrosine kinase;
activation ofphospholipase C-,y 1 appears to be a promisingcandidate [17,18].
CellularDistribution ofTGFat
TGFa expression is clearly not restricted to the embryonic and neoplastic state.
We were the first to demonstrate that TGFa is produced in vitro and in vivo by a
non-transformed epithelial cell, human keratinocytes [19]. Subsequently, production
of TGFa has been detected in a wide range of normal cells and tissues, including
activated macrophages [20], mammary epithelium [21,22], and gastrointestinal tis-
sues [23-28]. In the rat small intestine, epithelial cells eluted from the jejunal
crypt-villus axis expressed TGFamRNA at twofold higher levels in thevillustip than
in the crypt, and immunostaining forTGFa showed uniform immunoreactivity inthe
villus cells, whereas crypt cells did not stain [27]. Localization of TGFa in this
post-mitotic, differentiated compartment may have important implications for its
mode of action (see below). Production of TGFa in the stomach also will be
discussed in more detail below.
It should be noted that the examples cited above represent cells and tissues in
whichTGFamRNA, aswell asprotein, have beendetected, thusreflecting true local
synthesis rather than delivery from a remote site. Since EGF is expressed by a
selective population ofnormal cells and tissues (e.g., salivarygland, Brunner'sgland,
kidney), thewidespread production ofTGFa hasled us to suggest thatin vivo TGFa,
and not EGF, is the major ligand for the EGFR. This statement must be qualified by
certain caveats. First, Wright's group has demonstrated that a novel cell lineage
producesEGFinthechronicallyinjuredgastrointestinal tract [29]. Second, Snedeker
and co-workers have shown that both TGFa and EGF are expressed in the
developing mouse mammary gland but are restricted to different compartments;
TGFa co-localizes with EGFR to the proliferative terminal end bud compartment,
whereas EGF resides at the luminal surface, where it might play a role in fluid
transport and/or milk secretion [30]. Third, additional members of the EGF/TGFa
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FIG. 2. Family ofTGFa ligands and receptors.
family have been identified (seebelow), and certain ofthese ligands maybe aswidely
expressed as TGFa.
Family ofTGFaIEGFLigands andReceptors
Figure 2 lists the family ofTGFa ligands and receptors. EGF and EGFRwere the
first tobecharacterized [15]. Two additional receptorswith homology to EGFR have
been identified, erbB-2 and erbB-3 [31,32]. Of interest is the fact that a 44 kd
glycoprotein designated neu differentiation factor (NDF) has been purified to
homogeneity from ras-transformed rat cells and appears to be a ligand for erbB-2
[33]; this glycoprotein may be the rat homologue of a 45 kd protein heregulin-aL that
has been purified from the conditioned medium of a human breast cancer cell line
(MDA-MB-231), cloned, and sequenced [34]. Addition ofNDF to mammaryepithe-
lial cells results in a differentiated phenotype [35]. No ligand for erbB-3 has been
identified thus far.
There is an expanding number of members of the TGFa family of ligands. These
share structural similarities, including the conservation of six cysteines of the EGF
motifwhich, in EGF, are involved in the three disulfide bonds defining the tertiary
structure and conferring the ability to bind the EGFR. With the exception ofcripto
(for which recombinant peptide is not yet available), these family members have
been shown to bind the EGFR. The best characterized of these ligands are EGF,
TGFa, and amphiregulin (AR), whose structures are shown in Fig. 3. The disulfide
bonds formed between cysteines 1 and 3, 2 and 4, and 5 and 6 result in formation of
three loops that provide the backbone structure to these molecules. AR was initially
cloned from TPA-induced MCF-7 cells [36,37]; more recently, it has been isolated
from conditioned medium of human keratinocytes [38], in which, like TGFaL, it
appears to act as an autocrine growth factor. Newer members of the EGF/TGFa
familywhich have not been aswell characterized include heparin binding (HB)-EGF
and cripto. HB-EGF was cloned from human macrophages [39], and cripto was
identified initially in a human teratocarcinoma cell line [40].
Production of TGFa, AR, and cripto has been examined in gastrointestinal
neoplasia. In contrast to TGFa, production of AR and cripto appears to be more
consistently elevated in gastrointestinal neoplasms relative to normal gastrointesti-
nal epithelium. Salomon and co-workers have observed AR expression in normal
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colonic epithelium, but cripto expression was restricted to neoplastic tissue [41]. We
have observed AR expression to be consistently enhanced in gastric and colonic
carcinoma relative to adjacent normal epithelium; the expression is confined to the
epithelial versus stromal elementsbyin situhybridization [421. TGFatexpression was
variable in intensity between normal epithelium and carcinoma. It should be noted,
however, that enhanced expression ofAR is not restricted toneoplasia, as it was also
increased in the involved skin ofpatientswithpsoriasis [42].
BiologicalActionsofTGFox
The biological actions of TGFot and EGF have been reviewed recently in detail
[15]. These peptides share a similar spectrum ofactivity, since bothpeptides activate
the same receptor. Shared properties that are of potential importance to the
gastrointestinal tract include stimulation ofcellular proliferation [15], cell migration
[43,441, angiogenesis [451, and arterial blood flow[461, aswell as inhibition ofgastric
acid secretion [47]. Quantitative differences in activity have been reported. For
example, TGFa is more potent in stimulation of calcium release from fetal long
bones [481. Also, TGFet is more potent in stimulating regional arterial blood flow in
dogs; pre-treatment with EGF or TGFot desensitizes the vascular response to EGF
but not to TGFet [46]. No explanation for these differences in biological activity has
been reported; however, differential processing or degradation of ligand-receptor
complexes exist as possible mechanisms [49-51]. A final point to emphasize is that
thesepolypeptidesclearly subserve functions other thangrowth.
TGFot IN THE STOMIACH
Localization Studies andRole inAcidRegulation
Identification ofTGF(xexpression in humankeratinocytes spurred us to examine a
battery of normal cells and tissues for TGF(x production. TGFot mRNA expression
was detected in the scrapedgastric mucosa of a number ofspecies, includinghuman,
dog, guinea pig [26h, and rat [Coffey RJ: personal observation]. To further localize
TGFa production in the gastric mucosa, guinea pig gastric mucosa was separated
into a 65 percent pureparietal cell fraction and 95 percent pure chiefcell fractionby
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the differential centrifugation method of Raufman et al. [52]. The 4.8 kb TGFa
transcript was greatest in the parietal cell fraction (5.8-fold increase), but was also
enhanced in the chief cell fraction (1.9-fold increase) relative to the unfractionated
gastric mucosa. Like TGFot expression, EGFR mRNA expression was most intense
in the parietal cell-enriched fraction (7.8-fold increase), butwas also increased in the
chief cell-enriched fraction (2.7-fold increase) relative to the unfractionated guinea
piggastric mucosa [52].
These studies have been extended byexamination ofTGFa immunohistochemical
staining in the normal human adult gastric mucosa [53]. At the light microscopic
level, TGFa immunoreactivity is greater in the fundus than the antrum. Within the
fundus, TGFa immunoreactivity is most concentrated in parietal cells, although
other cell populations exhibit immunostaining, including surface mucous cells.
Furthermore, both TGFa (by radioimmunoassay) and EGFR (by Western blot
analysis) have been detected in H+, K+-ATPase-enriched fractions ofhuman gastric
mucosal membranes [Coffey RJ, Goldenring JR: unpublished observation]. In
addition, a 2.7-fold increase in immunoreactive TGFa released into gastric secre-
tions was observed over basal levels following pentagastrin administration to three
normal volunteers (142 + 16 pg/minute basal versus 382 + 168 pg/minute post-
pentagastrin). In a separate study, extremely low basal immunoreactive TGFa levels
(13 + 9 pg/minute) were detected in human saliva, which further decreased after
pentagastrin administration. Furthermore, we have previously shown that pre-
treatment with TGFa in isolated rabbit parietal cells results in a dose-dependent
reduction of histamine-stimulated, but not acetylcholine-stimulated [14C-aminopy-
rine uptake] [54]. These studies have led us to suggest an autocrine/intracrine role
forTGFa in the modulation ofgastric acid secretion. Atentative model is as follows:
TGFotfunctionallybinds to its receptorintubulovesicles ofquiescent parietal cells to
suppress basal acid production; parietal cell activation by secretagogues results in
fusion of tubulovesicles to the canaliculus, activation of H+, K+-ATPase and acid
production, a process which would dissociate TGFa from its receptor and lead to its
release intothegastriclumen. The net effectwouldbe to augment acidproductionby
removal of this acid inhibitory factor. Additional studies are under way to test the
valadity ofthis highly speculative model.
Mitogenic EffectofTGFot in the Stomach
TGFa has been shown to be mitogenic for cultured canine fundic epithelial cells
[55]. In collaborative studies with Michael Rutten, we have shown that TGFa is a
potentmitogen forcultured guineapiggastricmucouscells [56]. Infact, recombinant
human TGFa is at least tenfold more potent than recombinant human EGF in
stimulating the growth of these cells under serum-free conditions. Since these
cultured cells express a 4.8 kb TGFa transcript and have detectable TGFa binding
sites [Rutten MJ, Coffey RJ: unpublished observation], the elements are present for
a TGFa autocrine loop in the growth ofthese cells.
RoleofTGFot in Gastric Injury
There is an orderly temporal sequence ofreparative events following acute gastric
injury. Repair of superficial epithelial cell loss, a process that is dependent on cell
migration, begins within five minutes of acute injury and is nearly complete within
one hour. Deeper mucosal erosions may persist for five days after acute injury and
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require DNA synthesis for repair. Since TGFa mediates cell migration and is a
mitogen for a number of epithelial cells (including gastric mucous cells), we
postulated that TGFa might be upregulated following acute gastric injury so as to
participate in the subsequent reparative events. After orogastric administration of
both acidified sodium taurocholate and hydrochloric acid to induce acute gastric
injury in rats, enhanced TGFa expression was observed by Northern blot analysis of
mRNA isolated from scraped gastric mucosa [57]. In the taurocholate model, there
was a dose-dependent increase in TGFa mRNA expression four hours after orogas-
tric administration of5, 15, and 30 mM taurocholate. At the 30 mM dose, a 1.3-fold
increase in TGFamRNAexpressionwasobserved at one hour, increasing to 2.6-fold
at six hours, and returning to baseline at 24 hours. More striking was a tenfold
increase in levels of immunoreactive TGFa in the gastric juice 30 minutes after
administration of hydrochloric acid. This rapid appearance of TGFa probably
represents release of a biologically active transmembrane form of TGFa. Thus
production ofTGFa is enhanced in a time frame consistent with its participation in
subsequent reparative events, although these observations certainly do not prove
that TGFa acts in this manner.
In an additional set of experiments, we studied whether TGFa was protective to
the gastric mucosa against acute ethanol- and aspirin-induced injury [58]. Systemic
administration of TGFa dose-dependently decreased 100 percent ethanol-induced
gastric mucosal injury; an intraperitoneal dose of 50 p,g/kg delivered 15 minutes
prior to ethanol decreased macroscopicmucosalinjurybygreaterthan90percent. At
the microscopic level, TGFasignificantlyprevented deep gastricnecrotic lesions and
reduced disruption of surface epithelium. Pre-treatment with orogastric TGFa (200
,ug/kg) onlypartially (40 percent) decreased macroscopic ethanol damage. Intraper-
itoneal administration of TGFa at a dose of 10 ,ug/kg, which does not significantly
inhibit gastric acid secretion, decreased aspirin (200 mg/kg)-induced macroscopic
damage by greater than 80 percent. Thus TGFa is truly cytoprotective, as it protects
against acid-independent and acid-dependent forms of acute gastric injury. TGFa
protection did not seem to be mediated by prostaglandin, glutathione, or ornithine
decarboxylase-related events, as evidenced by lack of influence of the inhibition of
theirproduction. Pre-treatmentwiththe sulfhydryl blocking agent N-ethylmaleimide
partially abolished (40 percent) the protective effect ofTGFa.
In addition, systemic administration of TGFa resulted in a time- and dose-
dependent increase in levels of immunoreactive gastric mucin. Gastric mucin was
measured in lightly scraped gastric mucosa by a reverse enzyme-linked immunosor-
bent assay (ELISA) with an antibody that recognizes biologically active, insoluble
gastric mucin [59]. Fifteen and 30 minutes following intraperitoneal administration
of 100 ,ug/kg ofTGFa, there was, respectively, a 7.3- and 14.6-fold increase in levels
of gastric mucin, which corresponds to the timing of TGFa-induced mucosal
protection. The role ofgastric mucus as aprotective barrierfor the gastric mucosa is,
however, controversial [60-63]. Adherent mucus is reported to be permeable to
damaging agents such as ethanol and aspirin [63], which gain access through the gel
to the superficial epithelial cells. On the other hand, removal ofthe gelatinous layer
of mucus in cellular debris which formed after exposure of the gastric mucosa to 70
percent ethanol inhibited the protection against a rechallenge with the same
necrotizing agent [64]. Wepostulate thatthe TGFa-induced increase inthe adherent
mucous gel layer covering the epithelial surface may act as a dilutional barrier to
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FIG. 4. Light microscopy of gastric mucosa of
patients with MWn&trier's disease. A. Diastase
resistant, periodic acid-Schiff (PAS) staining of
fundus of a patient with fn6trier's disease. Note
foveolar hyperplasia with tortuosity of glands and
prominent PAS staining that represents increased
neutral mucin (x 15). B. Low power ofgastric#.., #~Z.r
mucosa from a second patient with MWn6trier's ~"f,
disease, with diffuse, intense TGFax immunostain-V
ing, using a monoclonal antibody to recombinant
human TGFa (Oncogene Sciences) at a dilution of
1.5 ,ug/ml (x 10); note extensive cystic dilatation of
glands. C. High power ofB (x 250).
damaging agents, may delay and/or restrict further damage induced by acid pepsin,
and may accelerate early reparative events. An alternative mechanism by which
mucin might protect the gastric mucosa is through its ability to scavenge toxic oxygen
metabolites [65], which are generatedbyethanol and aspirin [66]. The rapid increase
in mucin levels is probably due to release of pre-formed mucin. Studies are under
way to examine the effect of TGFa on rat gastric mucin mRNA expression and
protein production.
Upregulation ofTGFa in Menetrier's Disease
Menetrier's disease is an uncommon disorder characterized by enlarged gastric
folds with foveolar hyperplasia and glandular cystic dilatation [67-72]. Biochemical
features that are seen frequently include hypoproteinemia, hypochlorhydria, and
increased gastric mucin content. From the cumulative results ofseveral small series,
it has been reported that there is a 10-15 percent incidence of gastric cancer in
patients with Menetrier's disease [70], but its exact incidence is uncertain, since the
disease is rare, and few patients have been followed prospectively. The etiology of
this disorder is unknown. Since TGFa stimulates the growth ofgastric mucous cells,
inhibits gastric acid secretion, and increases gastric mucin content, we speculated
that its overproduction might be involved in a pathogenesis of this disorder.
Therefore, we characterized TGFa immunostaining in the gastric mucosa of four
patients with Menetrier's disease [53]. In contrast to the normal pattern of TGFot
immunostaining, in which TGFac appears most concentrated in parietal cells, there
was intense staining in the majority of mucous cells (Fig. 4). In one patient, from
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whom sufficient fresh tissue was obtained to isolate RNA, expression of TGFa and
EGFRwas increased in the gastric mucosa relative to a normal volunteer.
In addition, metallothionein (MT)-TGFa transgenic mice, which overexpress
TGFa in the gastric mucosa, exhibit a number of features characteristic of and
consistent with the diagnosis of Menetrier's disease, including foveolar hyperplasia
and glandular cystic dilatation, increased gastric neutral mucin staining, and reduced
basal and histamine-stimulated rates of acid production [53]. Our findings of
enhanced TGFa immunostaining in the gastric mucosa of four patients with Me-
netrier's disease (with increased TGFa in mRNA expression in one patient),
coupled with the histological lesions and altered functional characteristics in the
stomachs of MT-TGFa transgenic mice, provide compelling evidence for a role for
TGFot (or, more generally, an EGFR-linked signal transduction pathway) in the
pathogenesis ofMenetrier's disease.
SUMMARY
In this briefmanuscript, we have attempted to provide the readerwith a historical
perspective ofTGFa, with particular emphasis on its possible roles in normal gastric
physiology and howitsoverproduction in Menetrier's disease might contribute to the
pathogenesis ofthis disorder.
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